Eric Topol, MD’s Post

Very interesting. This new antibiotic specifically targets gram-negative bacteria, sparing the gut's healthy bacteria. It overcomes the challenges of penetrating the tough outer membranes of gram-negative bacteria without disrupting the gut microbiome. Additional reading: News articles on antibiotic that doesn't disrupt the gut microbiome Scientists develop antibiotic that spares healthy gut bacteria msn.com • 3 min read New antibiotic targets only gram-negative bacteria, sparing the gut cen.acs.org • 3 min read

A Groundbreaking Antibiotic Discovery: Sparing the Gut Microbiome While Targeting Gram-Negative Pathogens A team of scientists, including Kristen A. Muñoz and Rebecca J. Ulrich, have unveiled an innovative antibiotic named lolamicin. Published in Nature, this study addresses the challenge of treating Gram-negative bacterial infections while preserving the gut microbiome. The Problem with Current Antibiotics Gram-negative infections are tough to treat due to robust resistance mechanisms, often requiring broad-spectrum antibiotics. These antibiotics indiscriminately destroy beneficial gut bacteria, leading to dysbiosis and secondary infections like Clostridioides difficile. There’s an urgent need for pathogen-specific, microbiome-sparing antibiotics. The new antibiotic Lolamicin Lolamicin targets the lipoprotein transport system in Gram-negative bacteria, showing efficacy against over 130 multidrug-resistant clinical isolates. Its standout feature is its ability to spare the gut microbiome. In mouse models, it treated acute pneumonia and septicaemia without harming beneficial gut bacteria, thanks to low sequence homology of its target in pathogenic bacteria versus commensals. The Broader Implications Lolamicin sets a new standard for antibiotic development, offering a strategy to target pathogens while preserving the microbiome. This approach could revolutionize bacterial infection treatments, reducing secondary infection risks and promoting overall health. For further details, you can read the full study published in Nature #nature #innovation #antibiotic #biotic #microbiome #microbiota #lolamicin #gut #health

It is big for at least two reasons: 1. New antimicrobial targeting drug resistant strains 2. Deep understanding of host defenses as the mainstay of immunity

What a newsflash! In addition to my post yesterday on antimicrobial resistance, there is a post today by Eric Topol, MD on a similar topic. The journal Nature published a study on the discovery of a broad-spectrum antibiotic that is selective for pathogenic microflora but safe for the gut microflora. Why it matters? Because all previous antibiotics were not selective for pathogenic microflora and, when used, resulted in the death of commensal gut bacteria, among others. Based on the information in the article, we may have the first microbiome-sparing antibiotic. This is great news and gives us hope in the possibility of a scientific breakthrough in the search for new classes of antibiotics that are selective and effective at the same time. #Antibiotics #Nature #Microbiome

If you are a microbiome explorer or are just about to become one, join us to our FREE webinar Feb 16th, 2024 2-3 PM  Metabarcoding Analysis as a Sustainable Tool for Managing Plant Diseases. A case study on how to assess the impact of phytosanitary treatments on fruit microbiome structure and explore the potential of beneficial phytobiome members to enhance biological control strategies. 

Mouthwash Effects on the Oral Microbiome: Are They Good, Bad, or Balanced? 🦠🔍 Get the answers in this latest article from the #InternationalDentalJournal ➡️ https://lnkd.in/eP2f2ZxD

We are here with a new segment where our in house scientists - Sanober and Devika will bust all the myths regarding the gut microbiome and enlighten you with facts. Here’s one on gut bacteria and their role in our gut microbiome. #gutbacteria #gutmicrobiome #gutmicrobiota #guthealth #guthealthmatters #guthealing #gutmicrobiota #gutfriendly #mythvsfact #microbiomeresearch

good read for the many emerging microbiome enthusiasts:

Broiler producers yield real revenue when their flocks maintain a balanced microbiome. Compared to birds fed challenged and untreated feed, Termin-8 treatment reduced necrotic enteritis-related mortality by over 40% in addition to reducing percent mortality and removal by over 45%. Get the full study. https://hubs.ly/Q022KGy90

Broiler producers yield real revenue when their flocks maintain a balanced microbiome. Compared to birds fed challenged and untreated feed, Termin-8 treatment reduced necrotic enteritis-related mortality by over 40% in addition to reducing percent mortality and removal by over 45%. Get the full study. https://hubs.ly/Q022KGy90